#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-2	An	_
1-2	3-16	event-related	_
1-3	17-26	potential	_
1-4	27-32	study	_
1-5	33-35	of	_
1-6	36-43	spatial	_
1-7	44-51	working	_
1-8	52-58	memory	_
1-9	59-61	in	_
1-10	62-67	binge	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
1-11	68-76	drinking	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
1-12	77-84	college	_
1-13	85-93	students	_
1-14	94-98	This	_
1-15	99-104	study	_
1-16	105-109	used	_
1-17	110-123	event-related	http://maven.renci.org/NeuroBridge/neurobridge#DrugRelatedDisorder
1-18	124-134	potentials	http://maven.renci.org/NeuroBridge/neurobridge#DrugRelatedDisorder
1-19	135-136	(	http://maven.renci.org/NeuroBridge/neurobridge#DrugRelatedDisorder
1-20	137-141	ERPs	http://maven.renci.org/NeuroBridge/neurobridge#DrugRelatedDisorder
1-21	142-143	)	http://maven.renci.org/NeuroBridge/neurobridge#DrugRelatedDisorder
1-22	144-147	and	_
1-23	148-149	a	_
1-24	150-158	modified	_
1-25	159-166	spatial	_
1-26	167-173	2-back	_
1-27	174-178	task	_
1-28	179-181	to	_
1-29	182-193	investigate	_
1-30	194-201	spatial	_
1-31	202-209	working	_
1-32	210-216	memory	_
1-33	217-219	in	_
1-34	220-225	binge	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
1-35	226-234	drinking	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
1-36	235-236	(	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
1-37	237-239	BD	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
1-38	240-241	)	http://maven.renci.org/NeuroBridge/neurobridge#DrinkingBinge
1-39	242-249	college	_
1-40	250-258	students	http://maven.renci.org/NeuroBridge/neurobridge#StudyInstrument
1-41	259-260	.	_

2-1	261-266	Based	_
2-2	267-269	on	_
2-3	270-273	the	_
2-4	274-280	Korean	_
2-5	281-288	version	_
2-6	289-291	of	_
2-7	292-295	the	_
2-8	296-303	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
2-9	304-307	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
2-10	308-316	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
2-11	317-331	Identification	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
2-12	332-336	Test	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
2-13	337-338	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
2-14	339-346	AUDIT-K	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
2-15	347-348	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
2-16	349-352	and	_
2-17	353-360	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
2-18	361-364	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
2-19	365-378	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
2-20	379-380	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
2-21	381-384	AUQ	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
2-22	385-386	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
2-23	387-393	scores	_
2-24	394-395	,	_
2-25	396-408	participants	_
2-26	409-413	were	_
2-27	414-422	assigned	_
2-28	423-427	into	_
2-29	428-430	BD	_
2-30	431-432	(	_
2-31	433-434	n	_
2-32	435-436	=	_
2-33	437-439	25	_
2-34	440-441	)	_
2-35	442-445	and	_
2-36	446-452	non-BD	_
2-37	453-454	(	_
2-38	455-456	n	_
2-39	457-458	=	_
2-40	459-461	25	_
2-41	462-463	)	_
2-42	464-470	groups	_
2-43	471-472	.	_

3-1	473-476	The	_
3-2	477-485	modified	_
3-3	486-493	spatial	_
3-4	494-500	2-back	_
3-5	501-505	task	_
3-6	506-514	includes	_
3-7	515-524	congruent	_
3-8	525-526	,	_
3-9	527-538	incongruent	_
3-10	539-540	,	_
3-11	541-544	and	_
3-12	545-549	lure	_
3-13	550-560	conditions	_
3-14	561-564	and	_
3-15	565-577	participants	_
3-16	578-581	are	_
3-17	582-590	required	_
3-18	591-593	to	_
3-19	594-601	respond	_
3-20	602-604	as	_
3-21	605-612	rapidly	_
3-22	613-616	and	_
3-23	617-627	accurately	_
3-24	628-630	as	_
3-25	631-639	possible	_
3-26	640-642	to	_
3-27	643-646	the	_
3-28	647-656	congruent	_
3-29	657-664	stimuli	_
3-30	665-668	but	_
3-31	669-672	not	_
3-32	673-675	to	_
3-33	676-679	the	_
3-34	680-691	incongruent	_
3-35	692-695	and	_
3-36	696-700	lure	_
3-37	701-708	stimuli	_
3-38	709-710	.	_

4-1	711-714	The	_
4-2	715-717	BD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
4-3	718-721	and	_
4-4	722-728	non-BD	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
4-5	729-735	groups	_
4-6	736-745	exhibited	_
4-7	746-756	comparable	_
4-8	757-769	performances	_
4-9	770-772	on	_
4-10	773-776	the	_
4-11	777-784	spatial	_
4-12	785-791	2-back	_
4-13	792-796	task	_
4-14	797-800	but	_
4-15	801-804	the	_
4-16	805-807	BD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
4-17	808-813	group	_
4-18	814-820	showed	_
4-19	821-834	significantly	_
4-20	835-841	larger	_
4-21	842-844	P3	_
4-22	845-855	amplitudes	_
4-23	856-860	than	_
4-24	861-864	the	_
4-25	865-871	non-BD	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
4-26	872-877	group	_
4-27	878-879	.	_

5-1	880-892	Additionally	_
5-2	893-894	,	_
5-3	895-898	the	_
5-4	899-905	non-BD	_
5-5	906-911	group	_
5-6	912-918	showed	_
5-7	919-925	larger	_
5-8	926-928	P3	_
5-9	929-939	amplitudes	_
5-10	940-942	in	_
5-11	943-951	response	_
5-12	952-954	to	_
5-13	955-958	the	_
5-14	959-968	congruent	_
5-15	969-976	stimuli	_
5-16	977-985	compared	_
5-17	986-988	to	_
5-18	989-992	the	_
5-19	993-1004	incongruent	_
5-20	1005-1008	and	_
5-21	1009-1013	lure	_
5-22	1014-1021	stimuli	_
5-23	1022-1029	whereas	_
5-24	1030-1033	the	_
5-25	1034-1036	P3	_
5-26	1037-1047	amplitudes	_
5-27	1048-1050	in	_
5-28	1051-1054	the	_
5-29	1055-1057	BD	_
5-30	1058-1063	group	_
5-31	1064-1067	did	_
5-32	1068-1071	not	_
5-33	1072-1078	differ	_
5-34	1079-1092	significantly	_
5-35	1093-1098	among	_
5-36	1099-1102	the	_
5-37	1103-1108	three	_
5-38	1109-1119	conditions	_
5-39	1120-1121	.	_

6-1	1122-1127	These	_
6-2	1128-1135	results	_
6-3	1136-1144	indicate	_
6-4	1145-1149	that	_
6-5	1150-1153	the	_
6-6	1154-1156	BD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
6-7	1157-1168	individuals	_
6-8	1169-1176	exerted	_
6-9	1177-1184	greater	_
6-10	1185-1191	effort	_
6-11	1192-1194	to	_
6-12	1195-1203	maintain	_
6-13	1204-1215	performance	_
6-14	1216-1222	levels	_
6-15	1223-1233	comparable	_
6-16	1234-1236	to	_
6-17	1237-1243	non-BD	_
6-18	1244-1255	individuals	_
6-19	1256-1259	and	_
6-20	1260-1264	that	_
6-21	1265-1269	they	_
6-22	1270-1274	were	_
6-23	1275-1279	less	_
6-24	1280-1289	efficient	_
6-25	1290-1292	in	_
6-26	1293-1308	differentiating	_
6-27	1309-1311	or	_
6-28	1312-1322	allocating	_
6-29	1323-1334	attentional	_
6-30	1335-1344	resources	_
6-31	1345-1352	between	_
6-32	1353-1361	relevant	_
6-33	1362-1365	and	_
6-34	1366-1376	irrelevant	_
6-35	1377-1388	information	_
6-36	1389-1390	.	_

7-1	1391-1400	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
7-2	1401-1404	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
7-3	1405-1412	methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
7-4	1413-1419	Ethics	_
7-5	1420-1429	statement	_
7-6	1430-1433	The	_
7-7	1434-1446	participants	_
7-8	1447-1451	were	_
7-9	1452-1462	instructed	_
7-10	1463-1465	to	_
7-11	1466-1473	abstain	_
7-12	1474-1478	from	_
7-13	1479-1486	alcohol	_
7-14	1487-1498	consumption	_
7-15	1499-1502	for	_
7-16	1503-1505	48	_
7-17	1506-1507	h	_
7-18	1508-1513	prior	_
7-19	1514-1516	to	_
7-20	1517-1520	the	_
7-21	1521-1531	experiment	_
7-22	1532-1533	,	_
7-23	1534-1537	and	_
7-24	1538-1546	provided	_
7-25	1547-1554	written	_
7-26	1555-1563	informed	_
7-27	1564-1571	consent	_
7-28	1572-1577	after	_
7-29	1578-1587	receiving	_
7-30	1588-1589	a	_
7-31	1590-1601	description	_
7-32	1602-1604	of	_
7-33	1605-1608	the	_
7-34	1609-1614	study	_
7-35	1615-1616	.	_

8-1	1617-1620	The	_
8-2	1621-1629	students	_
8-3	1630-1634	were	_
8-4	1635-1639	paid	_
8-5	1640-1643	for	_
8-6	1644-1649	their	_
8-7	1650-1663	participation	_
8-8	1664-1665	.	_

9-1	1666-1670	This	_
9-2	1671-1676	study	_
9-3	1677-1680	was	_
9-4	1681-1689	approved	_
9-5	1690-1692	by	_
9-6	1693-1696	the	_
9-7	1697-1705	Sungshin	_
9-8	1706-1711	Women	_
9-9	1712-1713	’	_
9-10	1714-1715	s	_
9-11	1716-1726	University	_
9-12	1727-1740	Institutional	_
9-13	1741-1747	Review	_
9-14	1748-1753	Board	_
9-15	1754-1755	(	_
9-16	1756-1763	SSWUIRB	_
9-17	1764-1772	2016–017	_
9-18	1773-1774	)	_
9-19	1775-1776	.	_

10-1	1777-1789	Participants	_
10-2	1790-1793	The	_
10-3	1794-1802	detailed	_
10-4	1803-1813	procedures	_
10-5	1814-1816	of	_
10-6	1817-1820	the	_
10-7	1821-1832	participant	_
10-8	1833-1842	selection	_
10-9	1843-1850	process	_
10-10	1851-1855	have	_
10-11	1856-1860	been	_
10-12	1861-1870	described	_
10-13	1871-1881	previously	_
10-14	1882-1884	in	_
10-15	1885-1886	a	_
10-16	1887-1892	study	_
10-17	1893-1895	by	_
10-18	1896-1899	our	_
10-19	1900-1908	research	_
10-20	1909-1914	group	_
10-21	1915-1916	.	_

11-1	1917-1920	The	_
11-2	1921-1927	Korean	_
11-3	1928-1935	version	_
11-4	1936-1938	of	_
11-5	1939-1942	the	_
11-6	1943-1950	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
11-7	1951-1954	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
11-8	1955-1963	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
11-9	1964-1978	Identification	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
11-10	1979-1983	Test	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
11-11	1984-1985	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
11-12	1986-1993	AUDIT-K	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
11-13	1994-1995	,	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
11-14	1996-1997	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
11-15	1998-1999	,	_
11-16	2000-2007	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
11-17	2008-2011	Use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
11-18	2012-2025	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
11-19	2026-2027	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
11-20	2028-2031	AUQ	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
11-21	2032-2033	,	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
11-22	2034-2035	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseQuestionnaire
11-23	2036-2039	and	_
11-24	2040-2041	a	_
11-25	2042-2055	questionnaire	_
11-26	2056-2066	containing	_
11-27	2067-2072	items	_
11-28	2073-2078	about	_
11-29	2079-2086	alcohol	_
11-30	2087-2090	use	_
11-31	2091-2092	(	_
11-32	2093-2097	e.g.	_
11-33	2098-2099	,	_
11-34	2100-2109	frequency	_
11-35	2110-2112	of	_
11-36	2113-2115	BD	_
11-37	2116-2124	episodes	_
11-38	2125-2127	in	_
11-39	2128-2131	the	_
11-40	2132-2136	last	_
11-41	2137-2138	2	_
11-42	2139-2144	weeks	_
11-43	2145-2148	and	_
11-44	2149-2152	age	_
11-45	2153-2155	of	_
11-46	2156-2161	onset	_
11-47	2162-2164	of	_
11-48	2165-2172	alcohol	_
11-49	2173-2176	use	_
11-50	2177-2178	)	_
11-51	2179-2183	were	_
11-52	2184-2196	administered	_
11-53	2197-2199	to	_
11-54	2200-2203	310	_
11-55	2204-2211	college	_
11-56	2212-2220	students	_
11-57	2221-2222	.	_

12-1	2223-2226	For	_
12-2	2227-2231	this	_
12-3	2232-2237	study	_
12-4	2238-2239	,	_
12-5	2240-2242	BD	_
12-6	2243-2246	was	_
12-7	2247-2254	defined	_
12-8	2255-2260	based	_
12-9	2261-2263	on	_
12-10	2264-2267	the	_
12-11	2268-2276	quantity	_
12-12	2277-2278	,	_
12-13	2279-2288	frequency	_
12-14	2289-2290	,	_
12-15	2291-2294	and	_
12-16	2295-2300	speed	_
12-17	2301-2303	of	_
12-18	2304-2311	alcohol	_
12-19	2312-2323	consumption	_
12-20	2324-2325	;	_
12-21	2326-2332	either	_
12-22	2333-2337	four	_
12-23	2338-2339	(	_
12-24	2340-2346	female	_
12-25	2347-2348	)	_
12-26	2349-2351	or	_
12-27	2352-2356	five	_
12-28	2357-2358	(	_
12-29	2359-2363	male	_
12-30	2364-2365	)	_
12-31	2366-2372	drinks	_
12-32	2373-2375	in	_
12-33	2376-2377	a	_
12-34	2378-2383	short	_
12-35	2384-2390	period	_
12-36	2391-2393	of	_
12-37	2394-2398	time	_
12-38	2399-2403	more	_
12-39	2404-2408	than	_
12-40	2409-2413	once	_
12-41	2414-2420	during	_
12-42	2421-2424	the	_
12-43	2425-2433	previous	_
12-44	2434-2435	2	_
12-45	2436-2441	weeks	_
12-46	2442-2445	and	_
12-47	2446-2452	either	_
12-48	2453-2456	two	_
12-49	2457-2458	(	_
12-50	2459-2465	female	_
12-51	2466-2467	)	_
12-52	2468-2470	or	_
12-53	2471-2476	three	_
12-54	2477-2478	(	_
12-55	2479-2483	male	_
12-56	2484-2485	)	_
12-57	2486-2492	drinks	_
12-58	2493-2496	per	_
12-59	2497-2501	hour	_
12-60	2502-2503	.	_

13-1	2504-2513	According	_
13-2	2514-2516	to	_
13-3	2517-2520	the	_
13-4	2521-2526	World	_
13-5	2527-2533	Health	_
13-6	2534-2546	Organization	_
13-7	2547-2548	(	_
13-8	2549-2552	WHO	_
13-9	2553-2554	)	_
13-10	2555-2556	,	_
13-11	2557-2558	a	_
13-12	2559-2564	score	_
13-13	2565-2566	>	_
13-14	2567-2568	8	_
13-15	2569-2571	on	_
13-16	2572-2575	the	_
13-17	2576-2581	AUDIT	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
13-18	2582-2584	is	_
13-19	2585-2596	recommended	_
13-20	2597-2599	as	_
13-21	2600-2603	the	_
13-22	2604-2611	cut-off	_
13-23	2612-2617	point	_
13-24	2618-2621	for	_
13-25	2622-2629	problem	_
13-26	2630-2638	drinking	_
13-27	2639-2640	.	_

14-1	2641-2648	However	_
14-2	2649-2650	,	_
14-3	2651-2657	others	_
14-4	2658-2662	have	_
14-5	2663-2672	suggested	_
14-6	2673-2677	that	_
14-7	2678-2681	the	_
14-8	2682-2693	sensitivity	_
14-9	2694-2697	and	_
14-10	2698-2709	specificity	_
14-11	2710-2713	for	_
14-12	2714-2721	problem	_
14-13	2722-2730	drinking	_
14-14	2731-2734	are	_
14-15	2735-2742	highest	_
14-16	2743-2747	when	_
14-17	2748-2750	an	_
14-18	2751-2756	AUDIT	_
14-19	2757-2762	score	_
14-20	2763-2764	>	_
14-21	2765-2767	12	_
14-22	2768-2770	is	_
14-23	2771-2775	used	_
14-24	2776-2778	as	_
14-25	2779-2780	a	_
14-26	2781-2788	cut-off	_
14-27	2789-2790	.	_

15-1	2791-2793	An	_
15-2	2794-2799	AUDIT	_
15-3	2800-2805	score	_
15-4	2806-2807	>	_
15-5	2808-2810	26	_
15-6	2811-2820	indicates	_
15-7	2821-2824	the	_
15-8	2825-2836	possibility	_
15-9	2837-2839	of	_
15-10	2840-2847	alcohol	_
15-11	2848-2858	dependence	_
15-12	2859-2860	.	_

16-1	2861-2863	In	_
16-2	2864-2868	this	_
16-3	2869-2874	study	_
16-4	2875-2876	,	_
16-5	2877-2882	those	_
16-6	2883-2886	who	_
16-7	2887-2895	obtained	_
16-8	2896-2901	total	_
16-9	2902-2908	scores	_
16-10	2909-2911	of	_
16-11	2912-2917	12~26	_
16-12	2918-2920	on	_
16-13	2921-2924	the	_
16-14	2925-2932	AUDIT-K	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
16-15	2933-2934	,	_
16-16	2935-2938	had	_
16-17	2939-2944	drunk	_
16-18	2945-2949	four	_
16-19	2950-2951	(	_
16-20	2952-2958	female	_
16-21	2959-2960	)	_
16-22	2961-2963	or	_
16-23	2964-2968	five	_
16-24	2969-2970	(	_
16-25	2971-2975	male	_
16-26	2976-2977	)	_
16-27	2978-2985	glasses	_
16-28	2986-2990	more	_
16-29	2991-2995	than	_
16-30	2996-3000	once	_
16-31	3001-3007	during	_
16-32	3008-3011	the	_
16-33	3012-3020	previous	_
16-34	3021-3022	2	_
16-35	3023-3028	weeks	_
16-36	3029-3030	,	_
16-37	3031-3034	and	_
16-38	3035-3040	drank	_
16-39	3041-3045	more	_
16-40	3046-3050	than	_
16-41	3051-3054	two	_
16-42	3055-3056	(	_
16-43	3057-3063	female	_
16-44	3064-3065	)	_
16-45	3066-3068	or	_
16-46	3069-3074	three	_
16-47	3075-3076	(	_
16-48	3077-3081	male	_
16-49	3082-3083	)	_
16-50	3084-3091	glasses	_
16-51	3092-3095	per	_
16-52	3096-3100	hour	_
16-53	3101-3105	were	_
16-54	3106-3114	included	_
16-55	3115-3117	in	_
16-56	3118-3121	the	_
16-57	3122-3124	BD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
16-58	3125-3130	group	_
16-59	3131-3132	.	_

17-1	3133-3138	Those	_
17-2	3139-3142	who	_
17-3	3143-3151	obtained	_
17-4	3152-3157	total	_
17-5	3158-3164	scores	_
17-6	3165-3166	<	_
17-7	3167-3168	8	_
17-8	3169-3171	on	_
17-9	3172-3175	the	_
17-10	3176-3183	AUDIT-K	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
17-11	3184-3185	,	_
17-12	3186-3189	had	_
17-13	3190-3195	drunk	_
17-14	3196-3200	less	_
17-15	3201-3205	than	_
17-16	3206-3210	four	_
17-17	3211-3212	(	_
17-18	3213-3219	female	_
17-19	3220-3221	)	_
17-20	3222-3224	or	_
17-21	3225-3229	five	_
17-22	3230-3231	(	_
17-23	3232-3236	male	_
17-24	3237-3238	)	_
17-25	3239-3246	glasses	_
17-26	3247-3253	during	_
17-27	3254-3257	the	_
17-28	3258-3266	previous	_
17-29	3267-3268	2	_
17-30	3269-3274	weeks	_
17-31	3275-3276	,	_
17-32	3277-3280	and	_
17-33	3281-3286	drank	_
17-34	3287-3291	less	_
17-35	3292-3296	than	_
17-36	3297-3300	two	_
17-37	3301-3302	(	_
17-38	3303-3309	female	_
17-39	3310-3311	)	_
17-40	3312-3314	or	_
17-41	3315-3320	three	_
17-42	3321-3322	(	_
17-43	3323-3327	male	_
17-44	3328-3329	)	_
17-45	3330-3337	glasses	_
17-46	3338-3341	per	_
17-47	3342-3346	hour	_
17-48	3347-3351	were	_
17-49	3352-3360	included	_
17-50	3361-3363	in	_
17-51	3364-3367	the	_
17-52	3368-3374	non-BD	_
17-53	3375-3380	group	_
17-54	3381-3382	.	_

18-1	3383-3390	Because	_
18-2	3391-3399	parental	_
18-3	3400-3407	alcohol	_
18-4	3408-3411	use	_
18-5	3412-3415	can	_
18-6	3416-3425	influence	_
18-7	3426-3429	the	_
18-8	3430-3437	alcohol	_
18-9	3438-3441	use	_
18-10	3442-3444	of	_
18-11	3445-3450	their	_
18-12	3451-3460	offspring	_
18-13	3461-3462	,	_
18-14	3463-3466	the	_
18-15	3467-3473	Korean	_
18-16	3474-3481	version	_
18-17	3482-3484	of	_
18-18	3485-3488	the	_
18-19	3489-3497	Children	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveAbilitiesScreeningInstrument
18-20	3498-3500	of	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveAbilitiesScreeningInstrument
18-21	3501-3511	Alcoholics	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveAbilitiesScreeningInstrument
18-22	3512-3521	Screening	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveAbilitiesScreeningInstrument
18-23	3522-3526	Test	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveAbilitiesScreeningInstrument
18-24	3527-3528	(	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveAbilitiesScreeningInstrument
18-25	3529-3535	CAST-K	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveAbilitiesScreeningInstrument
18-26	3536-3537	,	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveAbilitiesScreeningInstrument
18-27	3538-3539	)	http://maven.renci.org/NeuroBridge/neurobridge#CognitiveAbilitiesScreeningInstrument
18-28	3540-3543	was	_
18-29	3544-3556	administered	_
18-30	3557-3559	to	_
18-31	3560-3568	identify	_
18-32	3569-3576	whether	_
18-33	3577-3589	participants	_
18-34	3590-3591	’	_
18-35	3592-3599	parents	_
18-36	3600-3603	had	_
18-37	3604-3605	a	_
18-38	3606-3613	history	_
18-39	3614-3616	of	_
18-40	3617-3620	AUD	http://maven.renci.org/NeuroBridge/neurobridge#Audiometer
18-41	3621-3622	;	_
18-42	3623-3628	those	_
18-43	3629-3632	who	_
18-44	3633-3641	obtained	_
18-45	3642-3643	a	_
18-46	3644-3649	score	_
18-47	3650-3651	>	_
18-48	3652-3653	6	_
18-49	3654-3656	on	_
18-50	3657-3660	the	_
18-51	3661-3667	CAST-K	_
18-52	3668-3672	were	_
18-53	3673-3681	excluded	_
18-54	3682-3686	from	_
18-55	3687-3690	the	_
18-56	3691-3698	present	_
18-57	3699-3704	study	_
18-58	3705-3706	.	_

19-1	3707-3709	To	_
19-2	3710-3717	control	_
19-3	3718-3721	for	_
19-4	3722-3728	levels	_
19-5	3729-3731	of	_
19-6	3732-3744	intelligence	_
19-7	3745-3746	,	_
19-8	3747-3754	anxiety	_
19-9	3755-3756	,	_
19-10	3757-3760	and	_
19-11	3761-3771	depression	_
19-12	3772-3773	,	_
19-13	3774-3777	the	_
19-14	3778-3784	Korean	_
19-15	3785-3793	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
19-16	3794-3806	Intelligence	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
19-17	3807-3812	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
19-18	3813-3814	(	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
19-19	3815-3819	KWIS	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
19-20	3820-3821	,	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
19-21	3822-3823	)	http://maven.renci.org/NeuroBridge/neurobridge#DigitSymbolSubstitutionOfTheWechslerAdultIntelligenceScaleRevised
19-22	3824-3825	,	_
19-23	3826-3837	Spielberger	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
19-24	3838-3839	’	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
19-25	3840-3841	s	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
19-26	3842-3853	State-Trait	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
19-27	3854-3861	Anxiety	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
19-28	3862-3871	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
19-29	3872-3873	(	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
19-30	3874-3878	STAI	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
19-31	3879-3880	,	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
19-32	3881-3882	)	http://maven.renci.org/NeuroBridge/neurobridge#TraitAnxietyInventory
19-33	3883-3884	,	_
19-34	3885-3888	and	_
19-35	3889-3900	Self-Rating	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
19-36	3901-3911	Depression	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
19-37	3912-3917	Scale	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
19-38	3918-3919	(	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
19-39	3920-3923	SDS	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
19-40	3924-3925	,	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
19-41	3926-3927	)	http://maven.renci.org/NeuroBridge/neurobridge#DepressionRatingScale
19-42	3928-3929	,	_
19-43	3930-3942	respectively	_
19-44	3943-3944	,	_
19-45	3945-3949	were	_
19-46	3950-3962	administered	_
19-47	3963-3964	.	_

20-1	3965-3977	Additionally	_
20-2	3978-3979	,	_
20-3	3980-3983	the	_
20-4	3984-3994	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
20-5	3995-4003	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
20-6	4004-4013	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
20-7	4014-4017	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
20-8	4018-4028	DSM-IV-Non	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
20-9	4029-4036	Patient	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
20-10	4037-4038	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
20-11	4039-4046	SCID-NP	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
20-12	4047-4048	,	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
20-13	4049-4050	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
20-14	4051-4054	was	_
20-15	4055-4067	administered	_
20-16	4068-4070	to	_
20-17	4071-4077	ensure	_
20-18	4078-4082	that	_
20-19	4083-4085	no	_
20-20	4086-4098	participants	_
20-21	4099-4102	had	_
20-22	4103-4115	neurological	_
20-23	4116-4117	,	_
20-24	4118-4129	psychiatric	_
20-25	4130-4139	disorders	_
20-26	4140-4143	and	_
20-27	4144-4156	drug/alcohol	_
20-28	4157-4162	abuse	_
20-29	4163-4164	.	_

21-1	4165-4174	Following	_
21-2	4175-4178	the	_
21-3	4179-4190	application	_
21-4	4191-4193	of	_
21-5	4194-4197	the	_
21-6	4198-4205	initial	_
21-7	4206-4215	inclusion	_
21-8	4216-4219	and	_
21-9	4220-4229	exclusion	_
21-10	4230-4238	criteria	_
21-11	4239-4240	,	_
21-12	4241-4243	46	_
21-13	4244-4252	students	_
21-14	4253-4257	were	_
21-15	4258-4264	placed	_
21-16	4265-4267	in	_
21-17	4268-4271	the	_
21-18	4272-4274	BD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
21-19	4275-4280	group	_
21-20	4281-4284	and	_
21-21	4285-4287	52	_
21-22	4288-4296	students	_
21-23	4297-4301	were	_
21-24	4302-4308	placed	_
21-25	4309-4311	in	_
21-26	4312-4315	the	_
21-27	4316-4322	non-BD	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
21-28	4323-4328	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
21-29	4329-4330	.	_

22-1	4331-4343	Subsequently	_
22-2	4344-4345	,	_
22-3	4346-4358	participants	_
22-4	4359-4362	who	_
22-5	4363-4367	were	_
22-6	4368-4372	left	_
22-7	4373-4379	handed	_
22-8	4380-4381	,	_
22-9	4382-4394	ambidextrous	_
22-10	4395-4396	,	_
22-11	4397-4400	had	_
22-12	4401-4410	histories	_
22-13	4411-4413	of	_
22-14	4414-4427	neurological/	_
22-15	4428-4439	psychiatric	_
22-16	4440-4449	disorders	_
22-17	4450-4451	,	_
22-18	4452-4454	or	_
22-19	4455-4458	who	_
22-20	4459-4466	refused	_
22-21	4467-4469	to	_
22-22	4470-4481	participate	_
22-23	4482-4486	were	_
22-24	4487-4491	also	_
22-25	4492-4500	excluded	_
22-26	4501-4505	from	_
22-27	4506-4509	the	_
22-28	4510-4515	study	_
22-29	4516-4517	.	_

23-1	4518-4528	Ultimately	_
23-2	4529-4530	,	_
23-3	4531-4536	there	_
23-4	4537-4541	were	_
23-5	4542-4544	25	_
23-6	4545-4557	participants	_
23-7	4558-4559	(	_
23-8	4560-4561	8	_
23-9	4562-4567	males	_
23-10	4568-4571	and	_
23-11	4572-4574	17	_
23-12	4575-4582	females	_
23-13	4583-4584	)	_
23-14	4585-4587	in	_
23-15	4588-4592	both	_
23-16	4593-4596	the	_
23-17	4597-4599	BD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
23-18	4600-4601	(	_
23-19	4602-4605	age	_
23-20	4606-4611	range	_
23-21	4612-4613	:	_
23-22	4614-4619	18–26	_
23-23	4620-4625	years	_
23-24	4626-4627	)	_
23-25	4628-4631	and	_
23-26	4632-4638	non-BD	_
23-27	4639-4640	(	_
23-28	4641-4644	age	_
23-29	4645-4650	range	_
23-30	4651-4652	:	_
23-31	4653-4658	19–27	_
23-32	4659-4664	years	_
23-33	4665-4666	)	_
23-34	4667-4673	groups	_
23-35	4674-4675	.	_

24-1	4676-4679	The	_
24-2	4680-4688	modified	_
24-3	4689-4696	spatial	_
24-4	4697-4703	2-back	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
24-5	4704-4708	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
24-6	4709-4710	A	_
24-7	4711-4719	modified	_
24-8	4720-4727	spatial	_
24-9	4728-4734	2-back	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
24-10	4735-4739	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
24-11	4740-4743	was	_
24-12	4744-4748	used	_
24-13	4749-4751	to	_
24-14	4752-4760	evaluate	_
24-15	4761-4768	spatial	_
24-16	4769-4776	working	_
24-17	4777-4783	memory	_
24-18	4784-4785	.	_

25-1	4786-4790	This	_
25-2	4791-4795	task	_
25-3	4796-4804	included	_
25-4	4805-4814	congruent	_
25-5	4815-4816	,	_
25-6	4817-4828	incongruent	_
25-7	4829-4830	,	_
25-8	4831-4834	and	_
25-9	4835-4839	lure	_
25-10	4840-4850	conditions	_
25-11	4851-4852	;	_
25-12	4853-4858	under	_
25-13	4859-4862	the	_
25-14	4863-4872	congruent	_
25-15	4873-4882	condition	_
25-16	4883-4884	,	_
25-17	4885-4888	the	_
25-18	4889-4898	locations	_
25-19	4899-4901	of	_
25-20	4902-4905	the	_
25-21	4906-4913	current	_
25-22	4914-4922	stimulus	_
25-23	4923-4926	and	_
25-24	4927-4930	the	_
25-25	4931-4939	stimulus	_
25-26	4940-4949	presented	_
25-27	4950-4953	two	_
25-28	4954-4960	trials	_
25-29	4961-4968	earlier	_
25-30	4969-4973	were	_
25-31	4974-4977	the	_
25-32	4978-4982	same	_
25-33	4983-4984	;	_
25-34	4985-4990	under	_
25-35	4991-4994	the	_
25-36	4995-5006	incongruent	_
25-37	5007-5016	condition	_
25-38	5017-5018	,	_
25-39	5019-5022	the	_
25-40	5023-5032	locations	_
25-41	5033-5035	of	_
25-42	5036-5039	the	_
25-43	5040-5047	current	_
25-44	5048-5056	stimulus	_
25-45	5057-5060	and	_
25-46	5061-5064	the	_
25-47	5065-5073	stimulus	_
25-48	5074-5083	presented	_
25-49	5084-5087	two	_
25-50	5088-5094	trials	_
25-51	5095-5102	earlier	_
25-52	5103-5107	were	_
25-53	5108-5117	different	_
25-54	5118-5119	;	_
25-55	5120-5123	and	_
25-56	5124-5129	under	_
25-57	5130-5133	the	_
25-58	5134-5138	lure	_
25-59	5139-5148	condition	_
25-60	5149-5150	,	_
25-61	5151-5154	the	_
25-62	5155-5163	stimulus	_
25-63	5164-5173	presented	_
25-64	5174-5177	one	_
25-65	5178-5183	trial	_
25-66	5184-5191	earlier	_
25-67	5192-5195	was	_
25-68	5196-5204	repeated	_
25-69	5205-5206	.	_

26-1	5207-5210	The	_
26-2	5211-5219	stimulus	_
26-3	5220-5221	,	_
26-4	5222-5223	a	_
26-5	5224-5227	red	_
26-6	5228-5234	square	_
26-7	5235-5236	,	_
26-8	5237-5240	was	_
26-9	5241-5250	presented	_
26-10	5251-5253	in	_
26-11	5254-5255	a	_
26-12	5256-5257	3	_
26-13	5258-5259	×	_
26-14	5260-5261	3	_
26-15	5262-5268	matrix	_
26-16	5269-5272	and	_
26-17	5273-5275	in	_
26-18	5276-5281	total	_
26-19	5282-5285	360	_
26-20	5286-5292	trials	_
26-21	5293-5294	(	_
26-22	5295-5304	congruent	_
26-23	5305-5306	,	_
26-24	5307-5318	incongruent	_
26-25	5319-5320	,	_
26-26	5321-5324	and	_
26-27	5325-5329	lure	_
26-28	5330-5337	stimuli	_
26-29	5338-5347	presented	_
26-30	5348-5351	108	_
26-31	5352-5353	,	_
26-32	5354-5357	198	_
26-33	5358-5359	,	_
26-34	5360-5363	and	_
26-35	5364-5366	54	_
26-36	5367-5372	times	_
26-37	5373-5374	,	_
26-38	5375-5387	respectively	_
26-39	5388-5389	)	_
26-40	5390-5394	were	_
26-41	5395-5407	administered	_
26-42	5408-5410	in	_
26-43	5411-5414	two	_
26-44	5415-5421	blocks	_
26-45	5422-5426	with	_
26-46	5427-5430	the	_
26-47	5431-5440	congruent	_
26-48	5441-5442	,	_
26-49	5443-5454	incongruent	_
26-50	5455-5456	,	_
26-51	5457-5460	and	_
26-52	5461-5465	lure	_
26-53	5466-5473	stimuli	_
26-54	5474-5483	presented	_
26-55	5484-5492	randomly	_
26-56	5493-5494	.	_

27-1	5495-5507	Participants	_
27-2	5508-5512	were	_
27-3	5513-5521	required	_
27-4	5522-5524	to	_
27-5	5525-5532	respond	_
27-6	5533-5535	as	_
27-7	5536-5546	accurately	_
27-8	5547-5550	and	_
27-9	5551-5558	quickly	_
27-10	5559-5561	as	_
27-11	5562-5570	possible	_
27-12	5571-5573	in	_
27-13	5574-5577	the	_
27-14	5578-5587	congruent	_
27-15	5588-5594	trials	_
27-16	5595-5598	but	_
27-17	5599-5602	not	_
27-18	5603-5610	respond	_
27-19	5611-5613	in	_
27-20	5614-5617	the	_
27-21	5618-5629	incongruent	_
27-22	5630-5633	and	_
27-23	5634-5638	lure	_
27-24	5639-5645	trials	_
27-25	5646-5647	.	_

28-1	5648-5649	A	_
28-2	5650-5659	crosshair	_
28-3	5660-5663	was	_
28-4	5664-5673	displayed	_
28-5	5674-5677	for	_
28-6	5678-5683	1,000	_
28-7	5684-5686	ms	_
28-8	5687-5690	and	_
28-9	5691-5695	then	_
28-10	5696-5699	the	_
28-11	5700-5708	stimulus	_
28-12	5709-5712	was	_
28-13	5713-5722	presented	_
28-14	5723-5726	for	_
28-15	5727-5730	500	_
28-16	5731-5733	ms	_
28-17	5734-5742	followed	_
28-18	5743-5745	by	_
28-19	5746-5747	a	_
28-20	5748-5753	1,000	_
28-21	5754-5756	ms	_
28-22	5757-5763	window	_
28-23	5764-5767	for	_
28-24	5768-5776	response	_
28-25	5777-5781	time	_
28-26	5782-5783	;	_
28-27	5784-5789	there	_
28-28	5790-5793	was	_
28-29	5794-5796	an	_
28-30	5797-5811	inter-stimulus	_
28-31	5812-5820	interval	_
28-32	5821-5823	of	_
28-33	5824-5829	2,500	_
28-34	5830-5833	ms.	_
28-35	5834-5841	E-PRIME	_
28-36	5842-5850	software	_
28-37	5851-5852	(	_
28-38	5853-5866	Psychological	_
28-39	5867-5875	Software	_
28-40	5876-5881	Tools	_
28-41	5882-5886	Inc.	_
28-42	5887-5888	,	_
28-43	5889-5899	Sharpsburg	_
28-44	5900-5901	,	_
28-45	5902-5904	PA	_
28-46	5905-5906	,	_
28-47	5907-5910	USA	_
28-48	5911-5912	)	_
28-49	5913-5916	was	_
28-50	5917-5921	used	_
28-51	5922-5925	for	_
28-52	5926-5929	all	_
28-53	5930-5940	operations	_
28-54	5941-5944	and	_
28-55	5945-5946	a	_
28-56	5947-5952	block	_
28-57	5953-5955	of	_
28-58	5956-5958	30	_
28-59	5959-5965	trials	_
28-60	5966-5969	was	_
28-61	5970-5982	administered	_
28-62	5983-5988	prior	_
28-63	5989-5991	to	_
28-64	5992-5995	the	_
28-65	5996-6008	experimental	_
28-66	6009-6016	session	_
28-67	6017-6019	to	_
28-68	6020-6026	ensure	_
28-69	6027-6031	that	_
28-70	6032-6035	the	_
28-71	6036-6048	participants	_
28-72	6049-6059	understood	_
28-73	6060-6063	the	_
28-74	6064-6076	instructions	_
28-75	6077-6078	.	_

29-1	6079-6082	The	_
29-2	6083-6088	three	_
29-3	6089-6094	types	_
29-4	6095-6097	of	_
29-5	6098-6105	stimuli	_
29-6	6106-6109	and	_
29-7	6110-6113	the	_
29-8	6114-6123	procedure	_
29-9	6124-6127	for	_
29-10	6128-6131	the	_
29-11	6132-6140	stimulus	_
29-12	6141-6153	presentation	_
29-13	6154-6157	are	_
29-14	6158-6169	illustrated	_
29-15	6170-6172	in	_
29-16	6173-6176	Fig	_
29-17	6177-6178	1	_
29-18	6179-6180	.	_

30-1	6181-6201	Electrophysiological	_
30-2	6202-6211	recording	_
30-3	6212-6221	procedure	_
30-4	6222-6242	Electrophysiological	_
30-5	6243-6251	activity	_
30-6	6252-6255	was	_
30-7	6256-6264	assessed	_
30-8	6265-6267	by	_
30-9	6268-6290	electroencephalography	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
30-10	6291-6292	(	_
30-11	6293-6296	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Thing
30-12	6297-6298	)	http://maven.renci.org/NeuroBridge/neurobridge#Thing
30-13	6299-6304	using	_
30-14	6305-6306	a	_
30-15	6307-6317	64-channel	_
30-16	6318-6326	Geodesic	_
30-17	6327-6333	Sensor	_
30-18	6334-6337	net	_
30-19	6338-6347	connected	_
30-20	6348-6350	to	_
30-21	6351-6352	a	_
30-22	6353-6363	64-channel	_
30-23	6364-6374	high-input	_
30-24	6375-6384	impedance	_
30-25	6385-6394	amplifier	_
30-26	6395-6396	(	_
30-27	6397-6400	Net	_
30-28	6401-6404	Amp	_
30-29	6405-6408	300	_
30-30	6409-6410	;	_
30-31	6411-6421	Electrical	_
30-32	6422-6431	Geodesics	_
30-33	6432-6433	,	_
30-34	6434-6440	Eugene	_
30-35	6441-6442	,	_
30-36	6443-6445	OR	_
30-37	6446-6447	,	_
30-38	6448-6451	USA	_
30-39	6452-6453	)	_
30-40	6454-6456	in	_
30-41	6457-6458	a	_
30-42	6459-6469	soundproof	_
30-43	6470-6473	and	_
30-44	6474-6486	electrically	_
30-45	6487-6495	shielded	_
30-46	6496-6508	experimental	_
30-47	6509-6513	room	_
30-48	6514-6515	.	_

31-1	6516-6519	All	_
31-2	6520-6530	electrodes	_
31-3	6531-6535	were	_
31-4	6536-6546	referenced	_
31-5	6547-6549	to	_
31-6	6550-6552	Cz	_
31-7	6553-6556	and	_
31-8	6557-6566	impedance	_
31-9	6567-6570	was	_
31-10	6571-6581	maintained	_
31-11	6582-6584	at	_
31-12	6585-6587	50	_
31-13	6588-6590	kΩ	_
31-14	6591-6593	or	_
31-15	6594-6598	less	_
31-16	6599-6600	.	_

32-1	6601-6604	Eye	_
32-2	6605-6614	movements	_
32-3	6615-6618	and	_
32-4	6619-6625	blinks	_
32-5	6626-6630	were	_
32-6	6631-6640	monitored	_
32-7	6641-6643	by	_
32-8	6644-6654	electrodes	_
32-9	6655-6665	positioned	_
32-10	6666-6670	near	_
32-11	6671-6674	the	_
32-12	6675-6680	outer	_
32-13	6681-6688	canthus	_
32-14	6689-6692	and	_
32-15	6693-6700	beneath	_
32-16	6701-6704	the	_
32-17	6705-6709	left	_
32-18	6710-6713	eye	_
32-19	6714-6715	.	_

33-1	6716-6719	All	_
33-2	6720-6723	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
33-3	6724-6732	activity	_
33-4	6733-6736	was	_
33-5	6737-6745	recorded	_
33-6	6746-6758	continuously	_
33-7	6759-6764	using	_
33-8	6765-6766	a	_
33-9	6767-6775	0.01~400	_
33-10	6776-6778	Hz	_
33-11	6779-6787	bandpass	_
33-12	6788-6794	filter	_
33-13	6795-6798	and	_
33-14	6799-6800	a	_
33-15	6801-6809	sampling	_
33-16	6810-6814	rate	_
33-17	6815-6817	of	_
33-18	6818-6821	500	_
33-19	6822-6824	Hz	_
33-20	6825-6826	;	_
33-21	6827-6836	collected	_
33-22	6837-6840	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
33-23	6841-6845	data	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
33-24	6846-6850	were	_
33-25	6851-6860	digitally	_
33-26	6861-6869	filtered	_
33-27	6870-6875	using	_
33-28	6876-6877	a	_
33-29	6878-6884	0.3~30	_
33-30	6885-6887	Hz	_
33-31	6888-6896	bandpass	_
33-32	6897-6903	filter	_
33-33	6904-6905	.	_

34-1	6906-6910	Next	_
34-2	6911-6912	,	_
34-3	6913-6916	the	_
34-4	6917-6920	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
34-5	6921-6925	data	_
34-6	6926-6930	from	_
34-7	6931-6934	the	_
34-8	6935-6944	congruent	_
34-9	6945-6946	,	_
34-10	6947-6958	incongruent	_
34-11	6959-6960	,	_
34-12	6961-6964	and	_
34-13	6965-6969	lure	_
34-14	6970-6980	conditions	_
34-15	6981-6985	were	_
34-16	6986-6995	segmented	_
34-17	6996-7000	into	_
34-18	7001-7006	1,000	_
34-19	7007-7009	ms	_
34-20	7010-7016	epochs	_
34-21	7017-7018	(	_
34-22	7019-7028	including	_
34-23	7029-7030	a	_
34-24	7031-7034	100	_
34-25	7035-7037	ms	_
34-26	7038-7050	pre-stimulus	_
34-27	7051-7057	period	_
34-28	7058-7059	)	_
34-29	7060-7064	that	_
34-30	7065-7069	were	_
34-31	7070-7088	baseline-corrected	_
34-32	7089-7090	.	_

35-1	7091-7097	Epochs	_
35-2	7098-7110	contaminated	_
35-3	7111-7113	by	_
35-4	7114-7123	artifacts	_
35-5	7124-7128	were	_
35-6	7129-7136	removed	_
35-7	7137-7142	prior	_
35-8	7143-7145	to	_
35-9	7146-7155	averaging	_
35-10	7156-7157	(	_
35-11	7158-7163	based	_
35-12	7164-7166	on	_
35-13	7167-7168	a	_
35-14	7169-7178	threshold	_
35-15	7179-7181	of	_
35-16	7182-7183	a	_
35-17	7184-7196	peak-to-peak	_
35-18	7197-7206	amplitude	_
35-19	7207-7209	of	_
35-20	7210-7211	±	_
35-21	7212-7214	70	_
35-22	7215-7216	㎶	_
35-23	7217-7218	)	_
35-24	7219-7220	.	_

36-1	7221-7225	Then	_
36-2	7226-7229	all	_
36-3	7230-7239	remaining	_
36-4	7240-7244	data	_
36-5	7245-7249	were	_
36-6	7250-7258	averaged	_
36-7	7259-7268	according	_
36-8	7269-7271	to	_
36-9	7272-7275	the	_
36-10	7276-7285	congruent	_
36-11	7286-7287	,	_
36-12	7288-7299	incongruent	_
36-13	7300-7301	,	_
36-14	7302-7305	and	_
36-15	7306-7310	lure	_
36-16	7311-7321	conditions	_
36-17	7322-7326	with	_
36-18	7327-7329	an	_
36-19	7330-7347	average-reference	_
36-20	7348-7362	transformation	_
36-21	7363-7364	.	_

37-1	7365-7368	The	_
37-2	7369-7373	mean	_
37-3	7374-7381	numbers	_
37-4	7382-7384	of	_
37-5	7385-7391	trials	_
37-6	7392-7400	included	_
37-7	7401-7403	in	_
37-8	7404-7407	the	_
37-9	7408-7417	congruent	_
37-10	7418-7419	,	_
37-11	7420-7431	incongruent	_
37-12	7432-7433	,	_
37-13	7434-7437	and	_
37-14	7438-7442	lure	_
37-15	7443-7453	conditions	_
37-16	7454-7457	for	_
37-17	7458-7461	the	_
37-18	7462-7464	BD	_
37-19	7465-7470	group	_
37-20	7471-7475	were	_
37-21	7476-7481	76.68	_
37-22	7482-7483	(	_
37-23	7484-7486	SD	_
37-24	7487-7488	=	_
37-25	7489-7494	20.20	_
37-26	7495-7496	)	_
37-27	7497-7498	,	_
37-28	7499-7505	156.32	_
37-29	7506-7507	(	_
37-30	7508-7510	SD	_
37-31	7511-7512	=	_
37-32	7513-7518	26.22	_
37-33	7519-7520	)	_
37-34	7521-7522	,	_
37-35	7523-7526	and	_
37-36	7527-7532	38.84	_
37-37	7533-7534	(	_
37-38	7535-7537	SD	_
37-39	7538-7539	=	_
37-40	7540-7544	7.90	_
37-41	7545-7546	)	_
37-42	7547-7548	,	_
37-43	7549-7561	respectively	_
37-44	7562-7563	.	_

38-1	7564-7567	The	_
38-2	7568-7572	mean	_
38-3	7573-7580	numbers	_
38-4	7581-7583	of	_
38-5	7584-7590	trials	_
38-6	7591-7599	included	_
38-7	7600-7602	in	_
38-8	7603-7606	the	_
38-9	7607-7616	congruent	_
38-10	7617-7618	,	_
38-11	7619-7630	incongruent	_
38-12	7631-7632	,	_
38-13	7633-7636	and	_
38-14	7637-7641	lure	_
38-15	7642-7652	conditions	_
38-16	7653-7656	for	_
38-17	7657-7660	the	_
38-18	7661-7667	non-BD	_
38-19	7668-7673	group	_
38-20	7674-7678	were	_
38-21	7679-7684	77.12	_
38-22	7685-7686	(	_
38-23	7687-7689	SD	_
38-24	7690-7691	=	_
38-25	7692-7697	20.04	_
38-26	7698-7699	)	_
38-27	7700-7701	,	_
38-28	7702-7708	157.00	_
38-29	7709-7710	(	_
38-30	7711-7713	SD	_
38-31	7714-7715	=	_
38-32	7716-7721	25.38	_
38-33	7722-7723	)	_
38-34	7724-7725	,	_
38-35	7726-7729	and	_
38-36	7730-7735	37.40	_
38-37	7736-7737	(	_
38-38	7738-7740	SD	_
38-39	7741-7742	=	_
38-40	7743-7748	10.71	_
38-41	7749-7750	)	_
38-42	7751-7752	,	_
38-43	7753-7765	respectively	_
38-44	7766-7767	.	_

39-1	7768-7771	The	_
39-2	7772-7775	two	_
39-3	7776-7782	groups	_
39-4	7783-7786	did	_
39-5	7787-7790	not	_
39-6	7791-7797	differ	_
39-7	7798-7811	significantly	_
39-8	7812-7814	in	_
39-9	7815-7820	terms	_
39-10	7821-7823	of	_
39-11	7824-7831	numbers	_
39-12	7832-7834	of	_
39-13	7835-7841	trials	_
39-14	7842-7844	in	_
39-15	7845-7848	the	_
39-16	7849-7858	congruent	_
39-17	7859-7860	(	_
39-18	7861-7862	t	_
39-19	7863-7864	(	_
39-20	7865-7867	48	_
39-21	7868-7869	)	_
39-22	7870-7871	=	_
39-23	7872-7875	.04	_
39-24	7876-7877	,	_
39-25	7878-7879	p	_
39-26	7880-7881	=	_
39-27	7882-7885	.94	_
39-28	7886-7887	)	_
39-29	7888-7889	,	_
39-30	7890-7901	incongruent	_
39-31	7902-7903	(	_
39-32	7904-7905	t	_
39-33	7906-7907	(	_
39-34	7908-7910	48	_
39-35	7911-7912	)	_
39-36	7913-7914	=	_
39-37	7915-7918	.08	_
39-38	7919-7920	,	_
39-39	7921-7922	p	_
39-40	7923-7924	=	_
39-41	7925-7928	.97	_
39-42	7929-7930	)	_
39-43	7931-7932	,	_
39-44	7933-7935	or	_
39-45	7936-7940	lure	_
39-46	7941-7942	(	_
39-47	7943-7944	t	_
39-48	7945-7946	(	_
39-49	7947-7949	48	_
39-50	7950-7951	)	_
39-51	7952-7953	=	_
39-52	7954-7958	-.54	_
39-53	7959-7960	,	_
39-54	7961-7962	p	_
39-55	7963-7964	=	_
39-56	7965-7968	.59	_
39-57	7969-7970	)	_
39-58	7971-7981	conditions	_
39-59	7982-7983	.	_

40-1	7984-7995	Statistical	_
40-2	7996-8004	analysis	_
40-3	8005-8016	Demographic	_
40-4	8017-8026	variables	_
40-5	8027-8031	were	_
40-6	8032-8040	analyzed	_
40-7	8041-8045	with	_
40-8	8046-8057	independent	_
40-9	8058-8065	t-tests	_
40-10	8066-8067	.	_

41-1	8068-8071	The	_
41-2	8072-8080	accuracy	_
41-3	8081-8085	rate	_
41-4	8086-8088	of	_
41-5	8089-8092	the	_
41-6	8093-8100	spatial	_
41-7	8101-8107	2-back	_
41-8	8108-8112	task	_
41-9	8113-8116	was	_
41-10	8117-8125	analyzed	_
41-11	8126-8130	with	_
41-12	8131-8132	a	_
41-13	8133-8150	repeated-measures	_
41-14	8151-8156	mixed	_
41-15	8157-8163	design	_
41-16	8164-8172	analysis	_
41-17	8173-8175	of	_
41-18	8176-8184	variance	_
41-19	8185-8186	(	_
41-20	8187-8192	ANOVA	_
41-21	8193-8194	)	_
41-22	8195-8200	using	_
41-23	8201-8210	condition	_
41-24	8211-8213	as	_
41-25	8214-8215	a	_
41-26	8216-8230	within-subject	_
41-27	8231-8237	factor	_
41-28	8238-8239	(	_
41-29	8240-8249	congruent	_
41-30	8250-8251	,	_
41-31	8252-8263	incongruent	_
41-32	8264-8265	,	_
41-33	8266-8269	and	_
41-34	8270-8274	lure	_
41-35	8275-8285	conditions	_
41-36	8286-8287	)	_
41-37	8288-8291	and	_
41-38	8292-8297	group	_
41-39	8298-8300	as	_
41-40	8301-8302	a	_
41-41	8303-8318	between-subject	_
41-42	8319-8325	factor	_
41-43	8326-8327	(	_
41-44	8328-8330	BD	_
41-45	8331-8334	and	_
41-46	8335-8341	non-BD	_
41-47	8342-8348	groups	_
41-48	8349-8350	)	_
41-49	8351-8352	.	_

42-1	8353-8361	Response	_
42-2	8362-8366	time	_
42-3	8367-8369	in	_
42-4	8370-8373	the	_
42-5	8374-8381	spatial	_
42-6	8382-8388	2-back	_
42-7	8389-8393	task	_
42-8	8394-8397	was	_
42-9	8398-8406	assessed	_
42-10	8407-8412	using	_
42-11	8413-8424	independent	_
42-12	8425-8432	t-tests	_
42-13	8433-8434	.	_

43-1	8435-8438	The	_
43-2	8439-8442	ERP	_
43-3	8443-8453	components	_
43-4	8454-8457	and	_
43-5	8458-8463	their	_
43-6	8464-8468	time	_
43-7	8469-8476	windows	_
43-8	8477-8481	were	_
43-9	8482-8492	determined	_
43-10	8493-8498	using	_
43-11	8499-8502	the	_
43-12	8503-8517	grand-averaged	_
43-13	8518-8522	ERPs	_
43-14	8523-8526	and	_
43-15	8527-8537	individual	_
43-16	8538-8541	ERP	_
43-17	8542-8551	waveforms	_
43-18	8552-8553	.	_

44-1	8554-8556	N2	_
44-2	8557-8560	was	_
44-3	8561-8568	defined	_
44-4	8569-8571	as	_
44-5	8572-8575	the	_
44-6	8576-8580	most	_
44-7	8581-8589	negative	_
44-8	8590-8594	peak	_
44-9	8595-8603	observed	_
44-10	8604-8606	at	_
44-11	8607-8611	from	_
44-12	8612-8619	170~340	_
44-13	8620-8622	ms	_
44-14	8623-8628	after	_
44-15	8629-8643	stimulus-onset	_
44-16	8644-8645	;	_
44-17	8646-8649	the	_
44-18	8650-8660	amplitudes	_
44-19	8661-8664	and	_
44-20	8665-8674	latencies	_
44-21	8675-8677	of	_
44-22	8678-8680	N2	_
44-23	8681-8685	were	_
44-24	8686-8694	analyzed	_
44-25	8695-8699	with	_
44-26	8700-8701	a	_
44-27	8702-8707	mixed	_
44-28	8708-8714	design	_
44-29	8715-8720	ANOVA	_
44-30	8721-8726	using	_
44-31	8727-8736	condition	_
44-32	8737-8740	and	_
44-33	8741-8750	electrode	_
44-34	8751-8755	site	_
44-35	8756-8757	(	_
44-36	8758-8760	F3	_
44-37	8761-8762	,	_
44-38	8763-8765	Fz	_
44-39	8766-8767	,	_
44-40	8768-8770	F4	_
44-41	8771-8772	,	_
44-42	8773-8776	FC3	_
44-43	8777-8778	,	_
44-44	8779-8782	FCz	_
44-45	8783-8784	,	_
44-46	8785-8788	FC4	_
44-47	8789-8790	,	_
44-48	8791-8793	C3	_
44-49	8794-8795	,	_
44-50	8796-8798	Cz	_
44-51	8799-8800	,	_
44-52	8801-8804	and	_
44-53	8805-8807	C4	_
44-54	8808-8809	)	_
44-55	8810-8812	as	_
44-56	8813-8827	within-subject	_
44-57	8828-8835	factors	_
44-58	8836-8839	and	_
44-59	8840-8845	group	_
44-60	8846-8848	as	_
44-61	8849-8850	a	_
44-62	8851-8866	between-subject	_
44-63	8867-8873	factor	_
44-64	8874-8875	.	_

45-1	8876-8878	P3	_
45-2	8879-8882	was	_
45-3	8883-8890	defined	_
45-4	8891-8893	as	_
45-5	8894-8897	the	_
45-6	8898-8902	most	_
45-7	8903-8911	positive	_
45-8	8912-8916	peak	_
45-9	8917-8921	from	_
45-10	8922-8929	250~550	_
45-11	8930-8932	ms	_
45-12	8933-8938	after	_
45-13	8939-8953	stimulus-onset	_
45-14	8954-8955	;	_
45-15	8956-8959	the	_
45-16	8960-8970	amplitudes	_
45-17	8971-8974	and	_
45-18	8975-8984	latencies	_
45-19	8985-8987	of	_
45-20	8988-8990	P3	_
45-21	8991-8995	were	_
45-22	8996-9004	analyzed	_
45-23	9005-9009	with	_
45-24	9010-9011	a	_
45-25	9012-9017	mixed	_
45-26	9018-9024	design	_
45-27	9025-9030	ANOVA	_
45-28	9031-9036	using	_
45-29	9037-9046	condition	_
45-30	9047-9050	and	_
45-31	9051-9060	electrode	_
45-32	9061-9065	site	_
45-33	9066-9067	(	_
45-34	9068-9070	F3	_
45-35	9071-9072	,	_
45-36	9073-9075	Fz	_
45-37	9076-9077	,	_
45-38	9078-9080	F4	_
45-39	9081-9082	,	_
45-40	9083-9086	FC3	_
45-41	9087-9088	,	_
45-42	9089-9092	FCz	_
45-43	9093-9094	,	_
45-44	9095-9098	FC4	_
45-45	9099-9100	,	_
45-46	9101-9103	C3	_
45-47	9104-9105	,	_
45-48	9106-9108	Cz	_
45-49	9109-9110	,	_
45-50	9111-9113	C4	_
45-51	9114-9115	,	_
45-52	9116-9118	P3	_
45-53	9119-9120	,	_
45-54	9121-9123	Pz	_
45-55	9124-9125	,	_
45-56	9126-9129	and	_
45-57	9130-9132	P4	_
45-58	9133-9134	)	_
45-59	9135-9137	as	_
45-60	9138-9152	within-subject	_
45-61	9153-9160	factors	_
45-62	9161-9164	and	_
45-63	9165-9170	group	_
45-64	9171-9173	as	_
45-65	9174-9175	a	_
45-66	9176-9191	between-subject	_
45-67	9192-9198	factor	_
45-68	9199-9200	.	_

46-1	9201-9214	Green-Geisser	_
46-2	9215-9226	corrections	_
46-3	9227-9231	were	_
46-4	9232-9236	used	_
46-5	9237-9240	for	_
46-6	9241-9251	violations	_
46-7	9252-9254	of	_
46-8	9255-9265	sphericity	_
46-9	9266-9269	and	_
46-10	9270-9273	the	_
46-11	9274-9283	corrected	_
46-12	9284-9292	p-values	_
46-13	9293-9296	are	_
46-14	9297-9305	reported	_
46-15	9306-9310	when	_
46-16	9311-9322	appropriate	_
46-17	9323-9324	.	_

